文献速递妇科

子宫内膜癌综合免疫分子图谱:一项三级医院回顾性研究

Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
PubMed 文献 · Gynecol Oncol · 2021-07-10

该回顾性研究对120例子宫内膜癌按ProMisE分类后进行扩展免疫组化(CD3、CD8、PD-L1、β-catenin、L1CAM)及44例的96基因NGS检测,发现综合免疫分子图谱可辅助判断非热点POLE变异的致病性,并识别免疫检查点抑制潜在获益者及可靶向改变如p53异常EC中的HER2扩增。

要点

  • 综合免疫分子图谱可辅助判断非热点POLE变异的致病性。
  • POLEmut和MMRd型EC常见CD3+/CD8+ TILs增多及PD-L1高表达。
  • p53异常型EC常见L1CAM高表达及HER2扩增(25%)。

核心结论

  • 综合免疫分子图谱为EC特征描述增加显著价值,可辅助判断非热点POLE变异致病性,并识别免疫检查点抑制潜在获益者及可靶向改变。

研究设计与样本

  • 三级医院回顾性研究,纳入120例连续EC,按ProMisE分类后进行扩展免疫组化,并对44例代表4个ProMisE亚组的EC行96基因NGS panel检测。

主要发现

  • 8例携带POLE变异,其中半数为热点变异;非热点POLE变异经TSO500分类为致病性3例、意义不明变异1例。
  • POLEmut和MMRd型EC通常显示更多CD3+/CD8+肿瘤浸润淋巴细胞及肿瘤浸润免疫细胞中更高的PD-L1表达。
  • p53异常型EC显示显著更高的L1CAM免疫反应性,常携带基因扩增包括HER2(25%),但通常缺乏ARID1A或PTEN变异。
  • β-catenin阳性和FGFR2变异主要见于NSMP型EC。

临床怎么用

  • 对EC行综合免疫分子图谱可辅助判断非热点POLE变异致病性。
  • 可识别可能从免疫检查点抑制中获益的EC患者。
  • 可 upfront 识别可靶向改变,如p53异常EC中的HER2扩增。

局限性

  • 回顾性研究设计。
  • NGS panel仅对44例子集进行检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Combined immunohistochemical and molecular classification using the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) independently predicts prognosis in endometrial carcinoma (EC). As next-generation sequencing (NGS) is entering clinical practice, we evaluated whether more comprehensive immunomolecular profiling (CIMP), including NGS and extended immunohistochemical analysis, could further refine the current ProMisE classification. METHODS: A series of 120 consecutive ECs, classified according to ProMisE, was stained immunohistochemically for CD3, CD8, PD-L1, beta-catenin and L1CAM. An in-house 96 gene NGS panel was performed on a subset of 44 ECs, representing the 4 ProMisE subgroups (DNA polymerase epsilon catalytic subunit exonuclease domain mutated (POLEmut), mismatch repair deficient (MMRd), p53 abnormal (p53 abn) and no specific molecular profile (NSMP) ECs). Cases harboring non-hotspot POLE variants were analyzed with Illumina TruSight Oncology 500 NGS panel (TSO500) as a surrogate for whole-exome sequencing. RESULTS: Eight cases harbored POLE variants, half of which were hotspots. Using TSO500, non-hotspot POLE variants were classified as pathogenic (3) or variant of unknown significance (1). POLEmut and MMRd ECs typically showed higher numbers of CD3+/CD8+ tumor-infiltrating lymphocytes and higher PD-L1 expression in tumor-infiltrating immune cells. p53 abn ECs showed significantly higher L1CAM immunoreactivity and frequently harbored gene amplifications including HER2 (25%), but typically lacked ARID1A or PTEN variants. Beta-catenin-positivity and FGFR2 variants were predominantly found in NSMP ECs. CONCLUSIONS: Our data show that CIMP adds significant value to EC characterization and may help to determine pathogenicity of non-hotspot POLE variants, encountered more frequently than expected in our series. In addition, CIMP may reveal ECs benefitting from immune checkpoint inhibition and allows upfront identification of targetable alterations, such as HER2 amplification in p53 abn ECs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Victoor J, Borght SV, Spans L, et al. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. Gynecol Oncol. 2021. PMID: 34253388. doi:10.1016/j.ygyno.2021.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。